Alzinova AB interim report January – March 2022
The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - March 2022Three months, January – March 2022 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -2,282,156 SEK (-1,461,253 SEK). · Earnings per share amounted to -0.14 SEK (-0.09 SEK). · Equity ratio amounted to 91.4% (93.6%). Significant events during January – March 2022 · Alzinova announced in January 2022 that the company had completed work on adapting the antibody to humans and selected a main candidate